Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human hepatocyte surface receptors, primarily CD81, SR-BI, and EphA2, serve as critical entry factors for Plasmodium falciparum sporozoites, including the 7G8 strain, during the liver stage of malaria infection. CD81 is a member of the tetraspanin family and is essential for the formation of the parasitophorous vacuole, a membrane-bound compartment where the parasite replicates. SR-BI and EphA2 also contribute to the invasion process, with their importance varying depending on the parasite strain and host environment. These receptors are considered high-value therapeutic targets for malaria prevention, as blocking their interaction with sporozoite surface proteins (such as P36 and P52) can prevent the establishment of infection. Research into these receptors often involves the use of monoclonal antibodies or small molecules to inhibit parasite entry, providing a foundation for pre-erythrocytic vaccine and drug development.
Blockade of host-pathogen protein-protein interaction
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human hepatocyte surface receptors (CD81, SR-BI, EphA2) (CD81/SR-BI/EphA2).